Table 4.

Characteristics of G-CSF therapy by ELA2 genotype

SCN group
CN group
NN
NM
P
NN
NM
P
No. patients   35   19   —   15   12   —  
Prevalence of patients undergoing G-CSF therapy, n (%)   15 (43)   18 (95)   .0001   6 (40)   9 (75)   NS  
Median G-CSF dose per injection, μg/kg (minimum-maximum)   9.2 (2-32)   9.9 (2.8-36)   NS   4.2 (1.6-5)   5.1 (2-9.9)   NS  
Frequency of G-CSF injections*
 		 2.1
 		 5.3
 		 .007
 		 5
 		 2.5
 		 NS
 
SCN group
CN group
NN
NM
P
NN
NM
P
No. patients   35   19   —   15   12   —  
Prevalence of patients undergoing G-CSF therapy, n (%)   15 (43)   18 (95)   .0001   6 (40)   9 (75)   NS  
Median G-CSF dose per injection, μg/kg (minimum-maximum)   9.2 (2-32)   9.9 (2.8-36)   NS   4.2 (1.6-5)   5.1 (2-9.9)   NS  
Frequency of G-CSF injections*
 		 2.1
 		 5.3
 		 .007
 		 5
 		 2.5
 		 NS
 

NS indicates not significant; NN genotype, patient with no ELA2 mutation; NM genotype, patient with a heterozygous ELA2 mutation; and —, not applicable.

*

Frequency of G-CSF injections is given for a 10-day period

View Large